{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibq2f3cnzs4e4uzxvuqf3f4mroiscdo4wit6efi5wm2gevqjbfwxu",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mgwary5w4u52"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiann2unrp3va7tuowvmclhrnj6adqol7tjc7snfig3t57ilpqh3mi"
    },
    "mimeType": "image/jpeg",
    "size": 86067
  },
  "path": "/2026/03/12/fda-telehealth-marketing-glp1-prescribers-behind-warning-letters/?utm_campaign=rss",
  "publishedAt": "2026-03-12T08:30:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Health tech",
    "Obesity",
    "patients",
    "Pharmaceuticals",
    "STAT+",
    "Telehealth",
    "weight loss"
  ],
  "textContent": "The FDA is targeting telehealth marketing of GLP-1 drugs. But those companies may not be the only ones under the microscope.",
  "title": "STAT+: The FDA is targeting telehealth marketing of GLP-1 drugs. Who’s prescribing them?",
  "updatedAt": "2026-03-12T14:42:45.000Z"
}